Born on Oct 1962,
Professor of Surgical Oncology,
Address: Department of Hepatobiliary Oncology, Sun Yat-sen University
Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, P R CHINA. 
E-mail: yfyuan@gzsums.edu.cn
Tel & Fax: (+86 20) 87343118. 
 
    Dr. Yunfei Yuan received his medical degree from Zhongshan (Sun Yat-sen) Medical College, Guangzhou, PR CHINA in 1983. From 1983 to 1986, He got his resident and research training in Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, PR China. Dr Yuan entered the same university for his postgraduate study in 1986 and got his Master of Medicine in 1989. Since then he pursued a surgical fellowship in abdominal oncology and held a position of attending surgeon in surgical oncology in Department of Abdominal Oncology in this cancer center in 1991. He moved up to the rank of an Associate Professor in Department of Hepatobiliary Oncology of this institute in 1997. Dr. Yuan is the author/co–author of over 30 publications and 2 book chapters.
    Dr. Yuan’s clinical practice and research focuses on hepatic and biliary malignancies. In Sep 2003, he began to perform orthotopic liver transplantation to treat patients with hepatocellular carcinoma and finished 19 cases until Sep 2004 without any operative mortality. He is also skillful at hepatectomy, including left (right) hemi hepatectomy or trisegmentectomy and two-step hepatectomy, and pancreatoduodenectomy. He performs transcatheter hepatic artery chemoembolization. He is the pioneer in PR China to evaluate the hepatic functional reserve for patients with hepatocellular carcinoma (HCC) with one parameter, retention rate of Indocyanine Green at 15 minutes (ICGR15), which help to decrease the morbidity of hepatic failure after hepatectomy or chemoembolization (Chinese Journal of Oncology, 1996, 17:377 ). He introduced the concept of high dose (>20ml) Lipiodol in the chemoembolization for patients with HCC. It means when patients hepatic functional reserve is good (ICGR15<10%), we might use high dose of embolization agent (e.g. Lipiodol) to kill HCC cells as much as possible without hepatic failure (Chinese Journal of Cancer 1997, 16:358).
    Recommended by Ministry of Health of CHINA, Dr Yuan got World Health Organization Fellowship in 1998(Ref: CHN NCD 001 FEL/2691/98). He worked in Baylor College of Medicine (BCM) from August 1998 to July 2000 and M.D. Anderson Cancer Center (MDA) from August 2000 to August 2001 as visiting scholar, both in Houston, Texas, USA. He got training in tumor molecular biology and cancer gene therapy, as well as in clinics of hepatic and biliary carcinoma. His research was focused on epigenetics and hunting the metastasis-relating genes in prostate cancer in BCM. He found that hypermethylation of CpG islands is the mechanism by which SYK is silenced in breast cancer and re-expression of SYK by inhibition of DNA methylation suppresses breast cancer cell invasiveness in MDA.
     After Dr. Yuan returned to Sun Yat-sen university, his research was focused on epigentics of hepatocellular carcinoma. Currently, he got research grants with nearly 1 million RMB. There are 4 postgraduate students and 1 technician in his research group.  
 
SELECTED PAPER:
1. Yuan Y, Mendez R, Sahin A, Dai JL, Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Research 2001, 61:5558-5561 
2. Yuan Y, Liu HJ, Sahin A, Dai JL. Re-established SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. International Journal of Cancer. (In Press)
3. Yuan YF, Li BK, Li JQ, et al. Long-term prognosis after hepatic resection for huge primary liver cancer. Chinese Journal of Cancer (Ai Zheng), 2004, 23(7):821-824
4. Yuan YF, Cui BK, Zhang YQ, Li SP, Chen MS, Guo RP, Lin XJ, Chen GH, Li JQ. Preliminary study on orthotopic liver transplantation for advanced hepatocellular carcinoma without extra-hepatic metastasis-- A Report of 10 cases. Chinese Journal of Cancer (Ai Zheng), 2004, 23(9):981-984
5. Yuan YF, Li JQ, Li BK, Zhang YQ, Li GH. Prognostic factors for long-term survival after resection of hepatocellular carcinoma. Chinese Journal of Practical Surgery. 2004，24(10):608-611
6. Yuan YF, Li JQ, Yang ZL, Wang JP. The Roles of DNA methylation in human neoplasms. Chinese Journal of Cancer (Ai Zheng). 2002, 21(11):1267-1277. (Review)
7. Yuan YF, Li JQ, Zhang YQ, et al. The evaluation of hepatic functional reserve during hepatectomy for patients with hepatocellular carcinoma. Chinese Journal of Surgery 1999, 37:327.
8. Yuan YF, Li GH, Li JQ, et al. The evaluation of hepatic cirrhosis severity during operation for patients with primary liver cancer. Chinese Journal of Cancer (Ai Zheng), 1997,16(1):58-59
9. Yuan YF, Li JQ, Li GH, et al. The evaluation of hepatic functional reserve for patients with primary liver carcinoma before the treatment of transcatheter hepatic artery chemoembolization. Chinese Journal of Cancer (Ai Zheng), 1997, 16(suppl):39
10. Yuan YF, Li JQ, Zhang YQ, et al. Two-step hepatectomy for primary liver carcinoma, Chinese Journal of Cancer (Ai Zheng), 1997, 16 (5):358.
11. Yuan YF, Li GH, Li JQ, et al. Preoperative evaluation of hepatic functional reserve for patients with primary liver carcinoma. Chinese Journal of Oncology (Zhonghua Zhong Liu Za Zhi), 1996, 17(5):377-380.
12. Yuan YF, Li GH, Li JQ, et al. The value of preoperative evaluation of the retention rate of Indocyanine Green for patients with primary liver carcinoma. Chinese Journal of Cancer (Ai Zheng), 1996, 15(4):277-279.
13. Yuan YF, Wang JF, Cheng SB. The Changes of the excretions of thromboxan B2 in urine after pancreas transplantation in rats. Chinese Journal of Organ Transplantation 1992, 13(1):5-7. 
 
GRANTS:
1. Project “SYK gene methylation, SYK protein expression, and Hepatocellular carcinoma invasion.” PI(Principal Investigator). Funded by CMB (China Medical Board of New York, Inc.). No: 98-677, US$ 70 000, 2003.1.1-2004.12.31.  
2. Project “Hypermethylation of tumor invasion related genes as biomarker of recurrence and metastases of hepatocellular carcinoma”. First applicant(PI), Funded by Department of Science and Technology of Guangdong Province of PR China. Grant No: 2002B30107.RMB 150000, 2003-2005.
3. Project “Hypermethylation of SYK gene in hepatocellular carcinoma”. First applicant(PI),Funded by Department of Health of Guangdong Province of PR China. Grant No:A2002230. RMB 10000. 2002-2004.
4. Project “Hypermethylation of Syk, E-cadherin and TIMP-3 in hepatocellular carcinoma”, First applicant(PI), Funded by Department of Education of Guangdong Province of PR China. Grant No:Q-univ02009. RMB 20000. 2002,9-2005,8.
5. Project “Clinical study on liver transplantation for treatment of liver cancer” PI. Funded by Sun Yat-sen University Cancer Center. RMB 5000, 2003-2005.
6. Project “Hypermethylation of hMLH1 gene in hepatocellular carcinoma” PI. Funded by Sun Yat-sen University Cancer Center. RMB 20000, 2003-2005.
7. Project "SYK gene methylation, SYK protein expression, and breast cancer invasion". The second applicant (PI: Dr. Jiale Dai in MD Anderson Cancer Center, USA). Funded by Department of Defense of USA. Grant No: DAMD17-02-1-0450. 2002-2005
8. Project “Clinical trial of interventional therapy and operation therapy for patients with hepatocellular carcinoma.”  PI: Dr Jinqing Li. Funded by Ministry of Science and Technology. Grant No. 96－907－03－02. RMB 500 000. 1997-2000. Sub-project. Liver functional reserve and liver cancer therapy. PI of sub-project.
9. Project “Study on Allele Loss and Cloning in Human Hepatocellular Carcinoma”. The fifth applicant (PI: Dr.Huiyun Wang). Funded by Natural Science Foundation of China. Grant No: 39670814. RMB 80,000. Jan 1997—Dec 1999.
10. Project "Study on the amplification of chromosome 1q and cloning in human HCC"，The third applicant (PI: Dr.Huiyun Wang).Funded by Natural Science Foundation of China ，Grant No: 39870799, RMB110,000，Jan 1999 -- Dec 2001,
11. Project “Study on prediction of recurrence and metastases after hepatectomy for patients with hepatocellular carcinoma” First applicant (PI). Funded by Science and Technology Committee of Guangdong Province, PR China. RMB 20000. 1996-1999.
12. Project “Evaluation of hepatic function reserve for patients with liver cancer before operation”. First applicant (PI). Funded by Sun Yat-sen University Cancer Center. RMB 3500.1991-1993.
13. Project “Evaluation of hepatic function reserve.” First applicant (PI). Funded by Sun Yat-sen University Cancer Center. RMB 2000, 1993-1995.
14. Project “Study of hepatic function reserve before transcatheter hepatic artery chemoembolization for patients with hepatocellular carcinoma.” First applicant (PI). Funded by Sun Yat-sen University Cancer Center. RMB 3000. 1996-1998. 
   
AWARDS:
1. Second Prize of Scientific and Technological Promoting of Universities in CHINA for the Project ‘Multimodality Treatments could Improve the Curative Effect for Primary Liver Carcinoma.’ in 2002 (4th author). No.2001-236..
2. Third Prize of Scientific and Technological Promoting of Guangzhou Municipality for the Project ‘Experimental and Clinical Research on Multimodality Treatments to Improve Curative Effect for Primary Liver Carcinoma’ in 2001 (4th author). No.Med-3-008-R04.
3. Second Prize of Scientific and Technological Promoting of Guangdong Province for the Project ‘Improvement of the Curative Effect for Primary Liver Carcinoma With Combination of Surgery with Intervention Therapy’ in 2002 (4th author). No.2001-Med-2-008-R04.
4. Second Prize of Scientific and Technological Promoting of Ministry of Education of CHINA for the Project ‘ Clinical and Experimental Research to Improve the Effect of Surgical Treatment for Primary Liver Carcinoma.’ in 1998 (9th author). No.98-219.
5. Second Prize of Medical Promoting of Sun Yat-sen University of Medical Science for the Project ‘ Increase the Survival Rate for Patients with Primary Liver Carcinoma after Hepatectomy’ in 1996 (3rd author). No.96-012.
6. Second Prize of Medical Promoting of Sun Yat-sen University of Medical Science for the Project ‘ Experimental study on transplantation of pancreas and islet’ in 1992(6th author). No.91-2-20. 
                                                                                Created on Sep 2002,
                                                                                Updated on Oct 2004